Hot Investor Mandate: Europe VC Raises New Fund for Early Stage Drugs and Platforms

19 Aug

A venture capital firm based in the Netherlands is raising a new fund, with a target of over EUR 100 million. The firm invests all over Europe, and the new fund will have the capacity to invest in the US as well. The firm invests up to EUR 12 million, and may make larger investments from the new fund. The firm generally leads financing rounds.

The firm focuses on therapeutic modalities and platforms, including small molecules, antibodies, cell therapies, and screening platforms including genetic screening. The fund is indication agnostic and typically invests at an early stage.

The firm is a very active investor and typically leads rounds, but can also be a follow-on investor. The firm also sometimes takes part in company generation and new spin-outs from universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: